Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Via | 2023 | Venture - Series Unknown | Undisclosed | New York |
| Aligos Therapeutics | 2025 | Post-IPO Equity | Undisclosed | San Francisco |
| Galecto | 2026 | Post-IPO Equity | Undisclosed | Copenhagen |
| ILiAD Biotechnologies | 2026 | Series D | Undisclosed | New York |
| Kailera Therapeutics | 2025 | Series B | $600.0M | Waltham |
| Galvanize Therapeutics | 2025 | Series C | $100.0M | San Carlos |
| Bambusa Therapeutics | 2025 | Series A | $90.0M | Boston |
| Attralus | 2024 | Series B | $56.0M | San Francisco |
| Parse Biosciences | 2023 | Series C | $50.0M | Seattle |
| TwinStrand Biosciences | 2023 | Venture - Series Unknown | $10.3M | Seattle |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | Via | Venture - Series Unknown | Undisclosed | New York, United States |
| 52 | Aligos Therapeutics | Post-IPO Equity | Undisclosed | San Francisco, United States |
| 53 | Galecto | Post-IPO Equity | Undisclosed | Copenhagen, Denmark |
| 54 | ILiAD Biotechnologies | Series D | Undisclosed | New York, United States |
| 55 | Kailera Therapeutics | Series B | $600.0M | Waltham, United States |
| 56 | Galvanize Therapeutics | Series C | $100.0M | San Carlos, United States |
| 57 | Bambusa Therapeutics | Series A | $90.0M | Boston, United States |
| 58 | Attralus | Series B | $56.0M | San Francisco, United States |
| 59 | Parse Biosciences | Series C | $50.0M | Seattle, United States |
| 60 | TwinStrand Biosciences | Venture - Series Unknown | $10.3M | Seattle, United States |
Via is a transport company that offers public mobility solutions for transit agencies, school districts, cities, and corporations.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.
Bambusa Therapeutics operates as biotechnology company.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Parse Biosciences is a biotechnology startup company that develops single-cell sequencing kit solutions for researchers.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.
Phathom Pharmaceuticals is a biopharmaceutical company.
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.
CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems.
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Janus Henderson Investors has invested in 175 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Life Science. The firm invests across 21 different industry categories.
Among tracked funding rounds, Kailera Therapeutics received $600.0M in a Series B round. Janus Henderson Investors's total known invested capital is $12.5B.
Janus Henderson Investors's average investment size is $129.0M across its portfolio of 175 companies.
Recent Janus Henderson Investors portfolio additions include Via, Aligos Therapeutics, Galecto, ILiAD Biotechnologies, Kailera Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors